[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615392":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":34,"locations":44,"responsibleParty":132,"collaborators":21,"id":134,"slug":21,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":21,"studyType":147,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":64,"whyStopped":21,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mirikizumab treatment","EXPERIMENTAL","Mirikizumab will be used as scheduled in the drug label: induction with IV infusions (900 mg) at week 0, week 4 and week 8.\n\nFor clinical responders: SC injections (300 mg) at W12 and every 4 weeks For clinical non-responders: SC injections (300 mg) at W12 and every 4 weeks",[13,14],"Drug: Mirikizumab - IV","Drug: Mirikizumab - SC",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Mirikizumab - IV","Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Mirikizumab - SC","SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders",[9],[27,31],{"name":28,"affiliation":29,"role":30},"Anthony BUISSON, MD","University Hospital, Clermont-Ferrand","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":33,"role":30},"Guillaume LE COSQUER, MD","CHU de Toulouse- Hôpital Rangueil",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":21,"email":39},"Julie MUSSOT","CONTACT","+33 6 27 49 29 10","jmussot@getaid.org",{"name":41,"role":37,"phone":42,"phoneExt":21,"email":43},"Noemie DA COSTA","+33 9 72 57 61 60","ndacosta@getaid.org",[45,62,76,90,104,118],{"facility":46,"status":47,"city":48,"state":21,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"CHU de Brest - Hôpital de la Cavale Blanche","NOT_YET_RECRUITING","Brest","29200","France",{"type":52,"coordinates":53},"Point",[54,55],-4.48628,48.39029,{"lat":55,"lon":54},[58],{"name":59,"role":37,"phone":60,"phoneExt":21,"email":61},"Franck CHOLET, MD","+33 2 98 34 71 15","franck.cholet@chu-brest.fr",{"facility":63,"status":64,"city":65,"state":21,"zip":66,"country":50,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"CHU de Clermont Ferrand - Hôpital d'Estaing","RECRUITING","Clermont-Ferrand","63003",{"type":52,"coordinates":68},[69,70],3.08682,45.77969,{"lat":70,"lon":69},[73],{"name":28,"role":37,"phone":74,"phoneExt":21,"email":75},"+33 4 73 75 05 23","a_buisson@chu-clermontferrand.fr",{"facility":77,"status":47,"city":78,"state":21,"zip":79,"country":50,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU de Nîmes Carémeau","Nîmes","30029",{"type":52,"coordinates":81},[82,83],4.35788,43.83665,{"lat":83,"lon":82},[86],{"name":87,"role":37,"phone":88,"phoneExt":21,"email":89},"Ludovic CAILLO, MD","+33 4 66 68 31 83","Ludovic.CAILLO@chu-nimes.fr",{"facility":91,"status":47,"city":92,"state":21,"zip":93,"country":50,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Institut Mutualiste Monsouris","Paris","75674",{"type":52,"coordinates":95},[96,97],2.3488,48.85341,{"lat":97,"lon":96},[100],{"name":101,"role":37,"phone":102,"phoneExt":21,"email":103},"Marion SIMON, MD","+33 1 56 61 63 14","Marion.Simon@imm.fr",{"facility":105,"status":47,"city":106,"state":21,"zip":107,"country":50,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"CHU de Toulouse - Hôpital Rangueil","Toulouse","31059",{"type":52,"coordinates":109},[110,111],1.44367,43.60426,{"lat":111,"lon":110},[114],{"name":115,"role":37,"phone":116,"phoneExt":21,"email":117},"Cyrielle GILLETTA, MD","+33 5 61 32 27 63","gilletta.c@chu-toulouse.fr",{"facility":119,"status":47,"city":120,"state":21,"zip":121,"country":50,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"CH de Valence","Valence","26000",{"type":52,"coordinates":123},[124,125],4.90956,44.9256,{"lat":125,"lon":124},[128],{"name":129,"role":37,"phone":130,"phoneExt":21,"email":131},"Céline MONTUCLARD, MD","+33475757512","cmontuclard@ch-valence.fr",{"type":133,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100615392",false,"NCT07292012","Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease","Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD","EMINENT-CD","Inclusion Criteria:\n\n* Patients with CD\n* ≥ 18 to ≤ 75 years-old\n* Symptomatic CD according to PRO-2 (stool \\> 3 or abdominal pain score \\> 1)\n* Transmural inflammation on baseline MRI (C-score \\> 0.5 in at least one segment)\n\nExclusion Criteria:\n\n* Prior exposure to anti-p19 biological therapy\n* Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase \\[JAK\\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents\n* Exclude any previous use of p19 IL23s agents\n* Contra-indication to mirikizumab\n* Definitive ostomy\n* Colectomy with IPAA\n* Isolated or uncontrolled perianal lesions\n* Severe obstructive symptoms\n* Intra-abdominal abscess\n* Contra-indication to MRI\n* No health insurance\n* Pregnant or lactating women\n* Patients already included in biomedical research other than an observational study (e.g., registry, cohort)\n* Concomitant Clostridioides difficile infection\n* HIV infection\n* Patient under guardianship, curatorship or safeguard of justice","ALL","18 Years","75 Years",{"count":145,"type":146},75,"ESTIMATED","INTERVENTIONAL",[149],"PHASE4","Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease",[152],"Crohn Disease (CD)",[154,155,156],"crohn's disease","transmural healing","mirikizumab","2026-05-21",{"date":159,"type":160},"2026-05-26","ACTUAL",{"date":162,"type":160},"2026-05-11",{"date":164,"type":146},"2028-11",{"name":5,"class":6},6]